Emerging Treatment Options in Inflammatory Bowel Disease

Nov 23, 2020 | health and medicine, Karger Publishers

In Collaboration With

Original Article Reference

This SciPod is a shortened and simplified summary of ‘Emerging Treatment Options in Inflammatory Bowel Disease’, published by Karger Publishers https://doi.org/10.1159/000507782

The complete original works are available at www.karger.com

About this episode

Inflammatory bowel disease (IBD) is a group of gastrointestinal conditions affecting almost 7 million people globally, and this incidence is rising. While treatments have improved over the last century, many patients do not respond sufficiently, especially those with moderate to severe levels of the disease. Novel drugs that restrain the immune system and reduce inflammation are being developed with the hope of improving patient outcomes. Dr Benjamin Misselwitz at Island Hospital of Bern and Bern University and his colleagues have conducted a comprehensive review of the emerging therapies and make recommendations for improving treatment for a wider range of patients.

 

 

 

This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

What does this mean?

Share: You can copy and redistribute the material in any medium or format

Adapt: You can change, and build upon the material for any purpose, even commercially.

Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.

Related episodes

Dr. Fay Betsou | The Hidden Life of a Biospecimen: Why Better Medical Research Begins Before the Laboratory Assay

Dr. Fay Betsou | The Hidden Life of a Biospecimen: Why Better Medical Research Begins Before the Laboratory Assay

To most of us, a vial of blood looks like a simple container of biological truth, a snapshot of what was happening inside a person at the moment the needle entered their arm. Scientists can measure its proteins, read genetic material, hunt for signs of disease, and feed the resulting data into increasingly powerful analytical systems. Yet that vial has a history. How long did it sit before processing? At what temperature? What kind of tube held it? Was it spun, transported, frozen, thawed, or stored? Each step may quietly change what researchers later believe they are seeing.

Prof. Shan Lu | Inducing Polyfunctional Antibodies: A Promising Chapter in the Long Search for an HIV Vaccine

Prof. Shan Lu | Inducing Polyfunctional Antibodies: A Promising Chapter in the Long Search for an HIV Vaccine

For more than four decades, HIV has challenged some of the brightest scientific minds in the world. Tremendous progress has transformed HIV from what was once almost always a fatal infection into a condition that can often be managed with modern medicines. Preventive treatments have also become increasingly effective. Yet millions of people continue to become infected every year, particularly in regions where access to healthcare remains limited. A safe, effective preventive HIV vaccine remains one of the greatest goals in global medicine because it has the potential to provide large-scale, long-lasting prevention for large numbers of high-risk populations.

Prof. Dr. Daniel Gredig | Protection Is a Conversation: How Modern HIV Prevention Is Changing Intimacy and Trust

Prof. Dr. Daniel Gredig | Protection Is a Conversation: How Modern HIV Prevention Is Changing Intimacy and Trust

The story of HIV prevention has changed dramatically over the past four decades. What was once dominated by fear and limited options has become a field shaped by scientific breakthroughs, greater understanding, and a growing appreciation of personal choice. Yet while medicine has transformed the ways people can protect themselves, one element remains as important as ever. Prevention depends on communication. Every intimate encounter involves two people, each bringing their own experiences, expectations, and preferences. Reaching a shared understanding is rarely as simple as it appears.

Professor Thomas Münzel | Nicotine: The Molecule the Tobacco Industry Doesn’t Want You to Question

Professor Thomas Münzel | Nicotine: The Molecule the Tobacco Industry Doesn’t Want You to Question

For decades, the story of tobacco and the heart seemed settled. Cigarettes were dangerous because they burned, releasing tar, carbon monoxide, and thousands of toxic chemicals that wrecked blood vessels. Remove the fire, the thinking went, and you remove almost all of the danger. That’s the logic behind heat-not-burn devices, e-cigarettes, and now nicotine pouches, each marketed, in turn, as the “safer” next step for people who can’t or won’t quit nicotine altogether.